Accéder au contenu
Merck

Retinoic acid-treated pluripotent stem cells undergoing neurogenesis present increased aneuploidy and micronuclei formation.

PloS one (2011-06-16)
Rafaela C Sartore, Priscila B Campos, Cleber A Trujillo, Bia L Ramalho, Priscilla D Negraes, Bruna S Paulsen, Tamara Meletti, Elaine S Costa, Leonardo Chicaybam, Martin H Bonamino, Henning Ulrich, Stevens K Rehen
RÉSUMÉ

The existence of loss and gain of chromosomes, known as aneuploidy, has been previously described within the central nervous system. During development, at least one-third of neural progenitor cells (NPCs) are aneuploid. Notably, aneuploid NPCs may survive and functionally integrate into the mature neural circuitry. Given the unanswered significance of this phenomenon, we tested the hypothesis that neural differentiation induced by all-trans retinoic acid (RA) in pluripotent stem cells is accompanied by increased levels of aneuploidy, as previously described for cortical NPCs in vivo. In this work we used embryonal carcinoma (EC) cells, embryonic stem (ES) cells and induced pluripotent stem (iPS) cells undergoing differentiation into NPCs. Ploidy analysis revealed a 2-fold increase in the rate of aneuploidy, with the prevalence of chromosome loss in RA primed stem cells when compared to naïve cells. In an attempt to understand the basis of neurogenic aneuploidy, micronuclei formation and survivin expression was assessed in pluripotent stem cells exposed to RA. RA increased micronuclei occurrence by almost 2-fold while decreased survivin expression by 50%, indicating possible mechanisms by which stem cells lose their chromosomes during neural differentiation. DNA fragmentation analysis demonstrated no increase in apoptosis on embryoid bodies treated with RA, indicating that cell death is not the mandatory fate of aneuploid NPCs derived from pluripotent cells. In order to exclude that the increase in aneuploidy was a spurious consequence of RA treatment, not related to neurogenesis, mouse embryonic fibroblasts were treated with RA under the same conditions and no alterations in chromosome gain or loss were observed. These findings indicate a correlation amongst neural differentiation, aneuploidy, micronuclei formation and survivin downregulation in pluripotent stem cells exposed to RA, providing evidence that somatically generated chromosomal variation accompanies neurogenesis in vitro.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Diméthylsulfoxyde, Hybri-Max, sterile-filtered, BioReagent, suitable for hybridoma, ≥99.7%
Sigma-Aldrich
Diméthylsulfoxyde, for molecular biology
Sigma-Aldrich
Diméthylsulfoxyde, ACS reagent, ≥99.9%
Sigma-Aldrich
Diméthylsulfoxyde, suitable for HPLC, ≥99.7%
Sigma-Aldrich
Diméthylsulfoxyde, sterile-filtered, BioPerformance Certified, meets EP, USP testing specifications, suitable for hybridoma
Sigma-Aldrich
Diméthylsulfoxyde, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Diméthylsulfoxyde, ≥99.5% (GC), suitable for plant cell culture
Sigma-Aldrich
TWEEN® 20, for molecular biology, viscous liquid
Sigma-Aldrich
TWEEN® 20, viscous liquid
Sigma-Aldrich
Triton X-100, for molecular biology
Sigma-Aldrich
Iodure de propidium, ≥94.0% (HPLC)
Sigma-Aldrich
TWEEN® 80, viscous liquid
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
TWEEN® 80, suitable for cell culture, suitable for insect cell culture, viscous liquid
Sigma-Aldrich
Pyruvate de sodium, powder, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥99%
Sigma-Aldrich
TWEEN® 20, viscous liquid, suitable for cell culture
Sigma-Aldrich
TWEEN® 20, BioXtra, viscous liquid